Bioiberica has received Frost & Sullivan’s 2025 European New Product Innovation Recognition in the innovative collagen solutions industry for its outstanding achievements in clinical validation, ingredient differentiation, and evidence-based product development. This achievement reflects the company’s consistent leadership in advancing scientifically validated collagen ingredients, strengthening its competitive position, and enabling customer-centric innovation in a complex and rapidly evolving European joint health and nutrition landscape.
Said Sreedevi Kakkad, Senior Research Analyst, TechVision, Frost & Sullivan: “Bioiberica distinguishes Collavant® n2 by providing mechanistic clarity and efficacy both in terms of joint comfort and potential cartilage preservation, setting it apart in a market that often lacks transparent clinical substantiation.”
Guided by a long-term growth strategy centred on science-first innovation, clinical research, and vertically integrated manufacturing, Bioiberica has demonstrated strong agility in the European collagen solutions market. Its sustained investment in native type II collagen research and pharmaceutical-grade production capabilities has enabled the company to address both clinical and lifestyle nutrition segments while maintaining full traceability and regulatory alignment.
Added Antonio Vendrell, Marketing & Communications Director, Bioiberica: “We’re honoured to receive this prestigious award, and we’d like to thank everyone who has contributed to this milestone – from our exceptional scientists and technical experts to our production specialists, regional distributors and more. To us, collagen is much more than just a molecule. It is a tool that, through in-depth research and refinement, unlocks virtually limitless opportunities for health and wellbeing innovation. Through our continuous efforts to clinically characterize the benefits of Collavant® n2, as well as our initiatives to dispel common myths and misconceptions in the collagen market, we hope to empower our industry partners to unlock the next generation of collagen innovation.”
Bioiberica’s commitment to customer success further strengthens its market position. The company supports finished-product manufacturers through clinical substantiation, formulation guidance, regulatory documentation, and validated delivery formats, including capsules, gummies, functional foods, and lifestyle-oriented nutrition products. Its collaborative approach reduces formulation risk and enables partners to accelerate commercialisation while maintaining scientific credibility and compliance with European regulations.
This award from Frost & Sullivan commends Bioiberica for setting a high benchmark in scientifically backed collagen innovation, manufacturing transparency, and customer collaboration. The company’s ability to integrate robust science, operational discipline, and market education continues to shape the future of the European innovative collagen solutions industry and support evidence-based product development at scale.
Each year, Frost & Sullivan presents the New Product Innovation Recognition to a company that demonstrates outstanding strategy development and execution, resulting in measurable differentiation, customer value creation, and strengthened competitive positioning. The recognition honours organisations that advance their industries through credible innovation and growth excellence. For more visit bioiberica.com
